Skip to main content

Table 3 Meta-analyses of randomized controlled trials that evaluated the association between sodium-glucose co-transporter 2 (SGLT2) inhibitors and the risk of fracture

From: Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

ReferencesNumber of studiesNumber of patientsMajor findingsComments
[28]3023,372Similar incidence of bone fractures in patients receiving SGLT2 inhibitors and placeboWhen the effects of canagliflozin, dapagliflozin, and empagliflozin on fractures were analyzed separately, none was associated with increased risk for fracture
[29]2720,895Similar incidence of bone fractures in patients receiving SGLT2 inhibitors and placeboIn groups at higher risk for fracture, including women and the elderly, no increase in the incidence of fracture was noted in patients treated with SGLT2 inhibitors